Name: Latest research reports of Lupin Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 1
Author: BOB Capital Markets Ltd.

Lupin Ltd.

NSE: LUPIN | BSE: 500257 | ISIN: INE326A01037 | Industry: Pharmaceuticals
| Falling Comet

1957.6000 52.00 (2.73%)

NSE Oct 09, 2025 15:55 PM

Volume: 2.3M

High volume today

Lupin Ltd.

04 Jun 2020

1957.60

2.73%

Lupin (ADD): Lupin/Mylan win approval for biosimilar Enbrel in Europe

Sell: Lupin Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Lupin (LPC) and partner Mylan have secured centralised marketing approval for Nepexto (biosimilar Etanercept) for European markets.

Lupin Ltd. has an average target of 2326.00 from 8 brokers.